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Abstract
Background: Clostridium difficile is the leading cause of infectious diarrhea in hospitalized patients. Its epidemiology
has shifted in recent years from almost exclusively infecting elderly patients in whom the gut microbiota has been
disturbed by antimicrobials, to now also infecting individuals of all age groups with no recent antimicrobial use.
Methods: A stochastic mathematical model was constructed to simulate the modern epidemiology of C. difficile in
a healthcare setting, and, to compare the efficacies of interventions.
Results: Both the rate of colonization and the incidence of symptomatic disease in hospital inpatients were
insensitive to antimicrobial stewardship and to the prescription of probiotics to expedite healthy gut microbiota
recovery, suggesting these to be ineffective interventions to limit transmission. Comparatively, improving hygiene
and sanitation and reducing average length of stay more effectively reduced infection rates. Although the majority
of new colonization events are a result of within-hospital ward exposure, simulations demonstrate the importance
of imported cases with new admissions.
Conclusions: By analyzing a wide range of screening sensitivities, we identify a previously ignored source of
pathogen importation: although capturing all asymptomatic as well as symptomatic introductions, individuals who
are exposed but not yet colonized will be missed by even a perfectly sensitive screen on admission. Empirical
studies to measure the duration of this latent period of infection will be critical to assessing C. difficile control
strategies. Moreover, identifying the extent to which the exposed category of individual contributes to pathogen
importation should be explicitly considered for all infections relevant to healthcare settings.
Background
Clostridium difficile is a Gram-positive, toxin-producing
anaerobic bacterium. Worldwide, it is the leading cause
of infectious diarrhea in hospitalized patients. The inci-
dence and severity of C. difficile infection (CDI) varies
considerably among studied populations but the general
trend shows an increase in recent decades [1-3], with a
higher proportion of CDI patients undergoing colectomy
and dying [4,5]. The disease is currently estimated to
cost $800 million per year in US acute care facilities [6].
Previously, persistently disturbed intestinal microbiota,
usually as a result of antimicrobials, was considered a
prerequisite of the disease. However, recent studies have
demonstrated severe cases occurring in groups that were
previously assumed to be low-risk, including pregnant
women, children and people with no recent exposure to
antimicrobials [7,8], indicating either a changing epi-
demiology or more testing in these groups [9].
There is increasing evidence for a potentially import-
ant role of asymptomatic carriage in the epidemiology of
CDI [10], with increasing rates recorded within
healthcare settings [11] and for the wider community
[12,13]. Hospital rooms occupied by asymptomatic pa-
tients can have very high rates of contamination (29%)
[14]. The dissociation between symptoms and infectivity
was recently corroborated by a prospective clinical study
in which 60% of patients still had skin contamination
following resolution of diarrhea in CDI patients, and
37% continued to shed spores in their stool [15]. Car-
riers have been implicated in the global spread of hyper-
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have caused over 2000 fatalities during the 2003–4 out-
break in Quebec, Canada [16]. Increased incidence, se-
verity of disease associated with endemic strains and
frequency of outbreaks emphasize the urgency for im-
proved epidemiological understanding. To this end, we
construct the most comprehensive epidemiological
model of CDI transmission reported to date and use it
to compare the efficacies of key interventions.
Surprisingly, there are only three modeling studies de-
scribing the mechanism of CDI transmission, each pro-
viding insight but with important limitations. The first
mathematical model of CDI by Starr and colleagues [17]
ignored asymptomatic carriage, a major potential source
of infection for this disease [11,18]. While this omission
was rectified by the authors in a subsequent study [19],
differential rates of progression to symptomatic disease
between patients who were and who were not taking an-
timicrobials [20] were not accounted for. The third mod-
eling study [21], developed by Lanzas and colleagues,
did not allow for symptomatic disease in patients who
were not on antimicrobials thereby overlooking a grow-
ing body of research showing high incidence rates in
previously healthy individuals to be a key feature of C.
difficile epidemiology [22,23]. Although parsimony
should always be a goal of epidemiological models, the
inclusion of greater biological realism in our simulations
highlights a hitherto unreported and potentially signifi-
cant source of infection. We use this stochastic model to
assess and compare the efficacies of several interventions
to reduce infection transmission. We discuss the signifi-
cance of our findings to infectious disease transmission
within healthcare settings in general as well as specific-
ally to the epidemiology of CDI.
Methods
The C. difficile pathogen
C. difficile is transmitted via the fecal-oral route. The in-
fectious dose is small and the bacterium is capable of
producing spores which can remain viable for years in
the environment [24]. There has been a recent sugges-
tion of inhalation of spores potentially providing a sec-
ondary mode of transmission [25,26], but this is unlikely
to contribute significantly to the disease’s epidemiology.
On ingestion, the pathogen colonizes the gut and the
host typically sheds bacteria in their stool within two
weeks.
A significant proportion of infections is asymptomatic,
with a spectrum of symptoms of varying severity experi-
enced by the remainder [14,27]. These symptoms in-
clude diarrhea, fever and abdominal pain and can result
in toxic megacolon and death. Reasons for the develop-
ment of symptomatic infection are incompletely under-
stood but the risk factor most commonly associated with
this progression is the disruption of normal gut micro-
biota by antimicrobials [28]. As a consequence of
disrupted gut microbiota and lack of local immunity, the
treatment of symptomatic infection with antimicrobials
is met with high relapse rates in patients who do not
successfully clear infection, as well as high reinfection
rates [29]. Our model is the first that allows for treated
individuals to return back to asymptomatically infected,
exposed or uncolonized states to reflect the fact that
treatment success is so variable. Following recent evi-
dence of an increasing trend in colonization and disease
in individuals who have not recently received antimicro-
bials [8], our model allows for the development of CDI
without antibiotic involvement.
Epidemiological model parameterization
Patients in a hospital with 1000 beds were simulated for
1 year. Individuals were stratified according to infection
status (Unexposed, Exposed, Colonized or Diseased) and
whether or not they were currently taking antimicrobials
(or had taken antimicrobials within the last 3 months).
Exposed, colonized and diseased patients all harbor the
pathogen; colonized and diseased patients contribute to
transmission, but only diseased patients exhibit symp-
toms. The overall structure of the model is described in
Figure 1. One novel component of our study is the in-
corporation of an ‘Exposed’ class of individuals which
explicitly allows for the fact that individuals who are not
colonized on admission may subsequently become colo-
nized regardless of within-hospital exposure. The epi-
demiological consequences of this addition are discussed
fully after the analysis.
Average length of stay was assumed to be 6 days,
reflecting rates that are typical of the US, Europe and
Australia [30]. Patients could be admitted in any of the
seven possible states but only discharged if they were
not suffering from symptomatic disease. The proportion
of new admissions that was taking (or had recently
taken) antimicrobials was assumed to be 25% and the
rates of antimicrobial prescription assumed that 50% of
the hospital inpatients were currently on antimicrobials
(or had taken them in the previous 3 months) [31,32].
Recovery of gut microbiota following cessation of anti-
microbial treatment was assumed to take 3 months [33].
New admissions were assumed to perfectly balance dis-
charges, resulting in a constant population size that ex-
perienced frequency-dependent transmission. This is
typical for the epidemiological modeling of human infec-
tious diseases [34].
After a period of 5 days, exposed individuals became
asymptomatically colonized [35]. For patients on antimi-
crobials, progression to symptomatic disease took a fur-
ther 5 days [20]. Patients not on antimicrobials were
assumed to be five-times less likely to progress to
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which took 10 days [36], was assumed to be 80% [37],
with the remaining treated patients returning to the ex-
posed category. The symptoms of 33% of patients with
CDI self-resolved [38] and 2% of symptomatic CDI pa-
tients died [20]. Table 1 summarizes the model parame-
ters and definitions with associated cited studies.
Mathematical model construction
Ordinary differential equations were constructed to
reflect the biology of infection as parsimoniously as
possible (Additional file 1). Traditionally, the basic
reproduction number, R0, is used to estimate transmis-
sion potential of an infectious disease. R0 is a useful
metric for estimating outbreak thresholds and is there-
fore of relevance in estimating risk of epidemic strains
introduced into fully susceptible (disease-free) popula-
tions. The stable endemicity of C. difficile within
healthcare settings represents a significant departure
from a disease-free population. Moreover, R0 no longer
quantifies risk nor discriminates between high levels and
low levels of transmission when constant imports of
pathogen are accounted for in healthcare settings [39].
Therefore, we present our results of control simulations
in terms of the incidence of symptomatic disease and
the ratio of colonized patients discharged from hospital
relative to patients colonized on admission. An advan-
tage of these measures of intervention efficacy is that
they can be directly measured.
Because the simulated population is small, infection
dynamics are more likely to be governed by stochastic
processes. Therefore, the ordinary differential equations
were converted into a stochastic simulation system
based on Gillespie’s direct method [40]. This method of
simulation accounts for continuous time but discrete
state space whereby the probability of conversion from
one state (e.g., Exposed) to another (e.g., Colonized) is
determined by the associate rate of the ordinary differen-
tial equation system. There are 15 possible epidemio-
logical state transitions in this system and they are
summarized in Table 2. The table shows the transfer of
individuals from one epidemiological compartment
(“-1”) to another (“+1”).
This stochastic model was used to compare the effi-
cacy of four different control measures in reducing the
rate of colonization within the hospital as well as the
Figure 1 Compartmental design of epidemiological model for Clostridium difficile. Individuals are either ‘U’nexposed, ‘E’xposed, ‘C’olonized
or ‘D’iseased and are increasingly ‘vul’nerable when they have taken antimicrobials (‘Ab’). Patients of all epidemiological states can be admitted
but only discharged if not symptomatic.
Table 1 Epidemiological model symbology and parameterization
Parameter Definition Value (,Vul) Reference
λ Recovery of gut microbiota (day
-1) 0.011 33
α Antibiotic treatment (day
-1) 0.11 31,32
β Exposure (day
-1) Full range SIM
η Dev into asympt infectious (day
-1) 0.2,0.2 35
θ Dev symptomatic CDI (day
-1) 0.04,0.2 20
ρ CDI treatment (day
-1) 0.1 36
σ Treatment failure (prop.) 0.2 37
ζ Self-resolving symptoms (prop.) 0.33 38
μ CDI case fatality rate (prop.) 0.02 20
κ Hospital discharge (day
-1) 0.17 30
ε Hospital admission (proportion) 0.75,0.25 31,32
Q Quarantined CDI ‘0’ yes, ‘1’ no n/a
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reducing the rate of antimicrobial prescription in order
to minimize the proportion of patients with heightened
vulnerability to symptomatic disease, 2) reducing the
level of environmental contamination and improving
hand hygiene, 3) administering probiotics to expedite
the restoration of healthy gut microbiota, and, 4) the re-
duction of average length of stay of inpatients.
The importance of asymptomatic patients in infection
transmission is a topic that has received a lot of recent
interest [10,11,41,42]. Despite this, the incubation periods
for C. difficile are less well defined than for other patho-
gens [9]. Simulating infection dynamics across a wide
range of incubation periods, we assessed the applicability
of screening for asymptomatic, as well as symptomatic,
admissions. Recent developments in commercially-
available PCR screening technology have provided a sensi-
tive (~90%) tool for rapidly detecting (~2 h) colonization
with C. difficile [43]. Therefore, we gauged the utility of
this screen as a further method of intervention under the
assumption that hospitals have the facilities to segregate
colonized (both asymptomatic and symptomatic) and
non-colonized patients.
Results and discussion
The temporal output from a typical stochastic simula-
tion run, using baseline parameterization and in the ab-
sence of intervention is shown in Figure 2. The top
panel shows the percentage of colonized individuals
discharged compared with the percentage of colonized
admissions. Average colonization prevalence on admis-
sion was 4.0% (st. dev. 2.0) which closely matches a re-
cent Canadian study that measured asymptomatic
admission prevalence of 4.4% in 6 hospitals in Quebec
2006–2007 [20]. We could not find clinical studies
measuring the prevalence of colonization on discharge
to directly corroborate our simulated values. However,
in our study, colonization and length of stay are inde-
pendent variables and so prevalence in discharged pa-
tients is representative of inpatient prevalence. Hospital
inpatient prevalence of endemic C. difficile varies a
Table 2 Epidemiological state transitions of the event-driven, stochastic model
Event Transition probability State change
Antibiotic treatment of uncolonized individual αUδtU -1, Uv+1
exposed individual αEδtE -1, Ev+1
colonized individual αCδtC -1, Cv+1
Gut microbiota recovery of uncolonized individual λUvδtU v-1, U+1
exposed individual λEvδtE v-1, E+1
colonized individual λCvδtC v-1, C+1
Exposure of individual without recent Ab use β[(C+Cv+DQ)U/N]δtU -1, E+1
individual with recent Ab use β[(C+Cv+DQ)Uv/N]δtU v-1, Ev+1
Colonization of individual without recent Ab use ηEδtE -1, C+1
individual with recent Ab use ηEvδtE v-1, Cv+1
Symptoms develop in indiv. without recent Ab use θCδtC -1, D+1
individual with recent Ab use θvCvδtC v-1, D+1
Symptoms resolve ζDδtD -1, Cv+1
Full clearance following treatment (1-σ)ρDδt D-1, Uv+1
Treatment does not result in full clearance σρDδt D-1, Ev+1
Figure 2 A typical simulation using baseline model
parameterization. Subplots show the percentage of Clostridium
difficile colonized patients who are admitted and discharged (top),
the incidence of symptomatic disease (middle) and the proportional
distribution of inpatient infection status (bottom). Stochastic (Direct
Gillespie algorithm) simulations are run for a hospital with 1000 beds
whereby newly admitted patients perfectly balance
discharged individuals.
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but our average colonization prevalence of 30% (st. dev.
5.6%) falls within the range described in the clinical lit-
erature [44].
The middle panel of Figure 2 shows the incidence of
symptomatic C. difficile infection which averages 2.8
cases per 1000 hospital bed days (st. dev. 4.2), also
within the range described in the most comprehensive
pan-European survey [45]. The very high rates of
underreporting that are known to occur for this patho-
gen, especially in younger patients who have less severe
symptoms, suggest that the true prevalence of infection
lies towards the top-end of estimates [46]. The bottom
panel shows the proportional distribution of the epi-
demiological states of hospital inpatients in which the
ratio of total (vulnerable or otherwise) Unexposed: Ex-
posed: Colonized: Diseased patients is 0.45: 0.26: 0.24:
0.05. Importantly, our baseline parameterization using
the most up-to-date data available for this pathogen sug-
gests that there are as many individuals in the ‘Exposed’
category as in the ‘Colonized’ category.
Figure 3 shows the sensitivity of two different outputs
(ratio of colonized patients discharged compared with
on admission, and, the incidence of symptomatic CDI),
to the four model parameters pertaining to control –
namely, the rate of antimicrobial prescription, the trans-
mission coefficient (reduced by improved hygiene and
sanitation), gut microbiota recovery rate (expedited with
probiotics) and average length of stay. Projections from
the model reinforce the clinical evidence supporting a
reduced length of stay [47,48] and infection control
[49-51] as effective methods for attenuating the spread
of C. difficile. While there is reassuring agreement be-
tween our model projections and clinical records of
intervention efficacy, there is also an important disparity
worth noting. Several recent studies have suggested anti-
microbial stewardship to be an effective method of redu-
cing the rate of CDI in hospitals [52-55]. However, these
include studies that examined stewardship in conjunc-
tion with infection control procedures [54,55], thereby
obscuring the efficacy of reduced prescription rates
alone. They also include studies that found either bor-
derline significant reduction in CDI (P=0.04, [53]) or no
statistical significance through a reduction in either
high-risk drugs or total antimicrobial usage in healthcare
settings (respectively, P=0.0597 and P=0.0823, [52]).
Therefore, the conflicting evidence for CDI reduction
through antimicrobial stewardship is in keeping with a
small effect size, as demonstrated by our simulations.
Infection rates were also insensitive to increased gut
microbiota recovery promoted by probiotics. Cautious
interpretation of this result is urged because while we
found the overall influence that this treatment has on
population-level transmission dynamics to be minimal, it
does not necessarily negate the individual-level health
benefits of probiotics.
Comparatively much greater returns were achieved by
reducing the length of stay and through improved hygiene
(respectively, bottom-right and top-right panel Figure 3).
Halving the average inpatient length of stay yielded almost
a 3-fold reduction in the colonized ratio of discharged
compared with admitted patients. Additionally, a 10-fold
decrease in CDI incidence was theoretically possible
through improved hygiene and sanitation practices. How-
ever, even in this scenario whereby complete elimination
of within-ward exposure was achieved (β=0), more pa-
tients left the hospital colonized than when they arrived.
This is due to the expedited progression of disease
resulting from antimicrobials, suggesting that stewardship
might come into play as a more influential control tool
once initial efforts have already eliminated ward-based
transmission.
A thorough sensitivity analysis of model input parame-
ters (see Additional file 2) demonstrates the robustness
of our results pertaining to infection control. However,
there are several limitations of this study that will re-
quire additional development and refinement. The life-
course of the pathogen is incompletely understood. Our
model structure assumes that all individuals who be-
come symptomatic must first pass through a phase of
shedding the pathogen asymptomatically. This follows
Figure 3 The effects of different control measures on
Clostridium difficile in the simulated hospital. The ratio of
patients colonized with C. difficile when discharged compared to
new admissions (left Y axis, points) are shown along with associated
incidence of symptomatic disease per 1000 hospital bed days (right
Y axis, crosses) across a wide range of the four tested control
measures: reducing antimicrobial prescription (top-left), improved
sanitation and hygiene (top-right), administering pro-biotics
(bottom-left) and reducing the average length of stay (bottom-
right). Each point is the average value of a 1-year simulation.
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carried out by Loo and coauthors in which the time to
developing symptomatic disease was measured to be
twice that for developing asymptomatic colonization
[20]. An alternative interpretation of this finding would
be that the individuals who develop symptomatic infec-
tion never pass through a phase of asymptomatic shed-
ding, but, instead, have a delayed progression of
colonization. However, this would imply that successful
colonization within patients that develop symptomatic
disease is somehow delayed. In the absence of definitive
evidence, therefore, our assumption seems more likely.
Another limitation of the study is the assumption that
asymptomatic shedders contribute equivalently to trans-
mission as symptomatically infected individuals. While
symptomatic disease involves a greater bacterial load,
asymptomatic shedding would not prompt the same
level of cautiousness in hygiene practices. Ascertaining
the relative contributions of both category of individual
will be a difficult, but important, issue to reconcile. Once
good, reproducible data become available on this differ-
ence, the model can easily be adjusted to incorporate the
additional information. A further limitation is the lack of
consideration for healthcare professionals (and, also,
hospital visitors) as vectors of infection – again, some-
thing that will require further development when the
epidemiological data become available. Greater complex-
ity can be iteratively incorporated into the framework
presented here to explore additional risk factors includ-
ing patient age as well as underlying co-morbidities and
patient immune status. Future directions for this work
also include assessing the integration of control tools.
Integrated control has been strategized with mathemat-
ical models for a number of infectious diseases including
sexually transmitted infections [56,57], vector-borne dis-
eases [58-60], newly emerging infections and pathogenic
bioterrorism attacks [61,62]. However, research into stra-
tegic combinations of healthcare-acquired infection con-
trol methods is underdeveloped.
Finally, we measured the sensitivity of the colonization
ratio and the incidence of CDI on the pathogen’s incuba-
tion period – the C. difficile life history parameter of
greatest uncertainty [9]. Intuitively, for shorter incuba-
tion periods, the colonization ratio increased along with
CDI incidence (Figure 4). This is because longer incuba-
tion periods delay the rate at which a pathogen can
spread between individuals. Remarkably, however, infec-
tion rates were extremely insensitive to screening sensi-
tivity. Even where screening was 100% sensitive (current
leading rapid screen sensitivity is ~90%) [43], little im-
pact on infection rates was achieved by the segregation
of all colonized admissions from non-colonized inpa-
tients. Recent studies have suggested that a large propor-
tion of patients colonized with C. difficile in healthcare
settings was likely exposed to the pathogen before they
were admitted [11,21,41,42]. These authors thereby attri-
bute a substantial role of asymptomatic individuals on
the importation of infection. In this analysis, by screen-
ing and subsequently isolating both asymptomatic and
symptomatic patients from the non-colonized inpatients,
we have eliminated these sources of infection and un-
covered a previously ignored and potentially important
source of C. difficile in healthcare settings: new admis-
sions who have been exposed to the pathogen but not
yet colonized.
Conclusions
Even a perfect screening test giving immediate results
for all new admissions will fail to detect the carriage
of C. difficile into the hospital by patients. Although
obtaining good estimates of the incubation period has
proven particularly difficult [9], it will be critical to
uncovering the extent to which the exposed category
of individuals influences the epidemiology of CDI.
This finding is not only relevant to C. difficile epi-
demiology, but to any pathogen that can be undetect-
ably transported by exposed individuals.
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Figure 4 The effects of screening on Clostridium difficile in the
simulated hospital. The ratio of patients that are colonized with C.
difficile when discharged relative to on admission (left) are shown
along with the associated incidence in symptomatic CDI per 1000
hospital bed days (right). Even highly sensitive screening (Y axis) can
do little to impact either of these epidemiological outcomes.
However, time to colonization (X axis), a component of the
pathogen’s life course for which data is absent, is highly influential
in its epidemiology.
Yakob et al. BMC Infectious Diseases 2013, 13:376 Page 6 of 8
http://www.biomedcentral.com/1471-2334/13/376Authors’ contributions
LY, TVR, DLP and ACAC contributed towards the design of the model. LY
constructed and analyzed the model. LY, TVR, DLP and ACAC wrote initial
drafts of the manuscript. LY, TVR, DLP and ACAC read and approved the final
manuscript.
Acknowledgements
The authors thank Camilla Wiuff and Jan Lindstrom for their useful
comments. The study was supported by funding from the National Health
and Medical Research Council of Australia, grant number APP1006243.
Author details
1School of Population Health, The University of Queensland, Brisbane,
Australia.
2School of Pathology and Laboratory Medicine, University of
Western Australia, Crawley, Australia.
3Centre for Clinical Research, The
University of Queensland, Brisbane, Australia.
Received: 18 March 2013 Accepted: 13 August 2013
Published: 16 August 2013
References
1. McDonald LC, Owings M, Jernigan DB: Clostridium difficile infection in
patients discharged from US short-stay hospitals, 1996–2003.
Emerg Infect Dis 2006, 12(3):409–415.
2. Wilcox MH, Smyth ET: Incidence and impact of clostridium difficile
infection in the UK, 1993–1996. J Hosp Infect 1998, 39(3):181–187.
3. Lo Vecchio A, Zacur G: Clostridium difficile infection: an update on
epidemiology, risk factors, and therapeutic options. Curr Opin
Gastroenterol 2012, 28:1–9.
4. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T,
Croyle K, Krystofiak S, Patel-Brown S, et al: A large outbreak of clostridium
difficile-associated disease with an unexpected proportion of deaths and
colectomies at a teaching hospital following increased fluoroquinolone
use. Infect Control Hosp Epidemiol 2005, 26(3):273–280.
5. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN: Increasing prevalence
and severity of clostridium difficile colitis in hospitalized patients in the
united states. Arch Surg 2007, 142(7):624–631.
6. McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P, Muder
RR, Lee BY: The economic burden of clostridium difficile. Clin Microbiol
Infect 2012, 18(3):282–289.
7. Benson L, Song X, Campos J, Singh N: Changing epidemiology of
clostridium difficile-associated disease in children. Infect Control Hosp
Epidemiol 2007, 28(11):1233–1235.
8. Clements ACA, Magalhaes RJS, Tatem AJ, Paterson DL, Riley TV: Clostridium
difficile PCR ribotype 027: assessing the risks of further worldwide
spread. Lancet Infect Dis 2010, 10(6):395–404.
9. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J,
Wilcox MH: Clinical practice guidelines for clostridium difficile infection
in adults: 2010 update by the society for healthcare epidemiology of
America (SHEA) and the infectious diseases society of america (IDSA).
Infect Control Hosp Epidemiol 2010, 31(5):431–455.
10. Curry SR, Muto CA, Schlackman JL, Pasculle AW, Shutt KA, Marsh JW,
Harrison LH: Use of MLVA genotyping to determine the role of
asymptomatic carriers in C. Difficile transmission. Clin Infect Dis 2013.
doi:10.1093/cid/cit475. in press.
11. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RLP, Donskey CJ:
Asymptomatic carriers are a potential source for transmission of
epidemic and nonepidemic clostridium difficile strains among long-term
care facility residents. Clin Infect Dis 2007, 45(8):992–998.
12. Dial S, Delaney JAC, Barkun AN, Suissa S: Use of gastric acid-suppressive
agents and the risk of community-acquired clostridium difficile-
associated disease. JAMA 2005, 294(23):2989–2995.
13. McFarland LV, Beneda HW, Clarridge JE, Raugi GJ: Implications of the
changing face of clostridium difficile disease for health care
practitioners. Am J Infect Control 2007, 35(4):237–253.
14. McFarland LV, Mulligan ME, Kwok RY, Stamm WE: Nosocomial acquisition
of clostridium difficile infection. N Engl J Med 1989, 320(4):204–210.
15. Sethi A, Al‐Nassir W, Nerandzic M, Bobulsky G, Donskey C: Persistence of
skin contamination and environmental shedding of clostridium difficile
during and after treatment of C. Difficile infection. Infect Control Hosp
Epidemiol 2010, 31(1):21–27.
16. Eggertson L: C. Difficile may have killed 2000 in quebec: study. Can Med
Assoc J 2005, 173(9):1020–1021.
17. Starr JM, Campbell A: Mathematical modeling of clostridium difficile
infection. Clin Microbiol Infect 2001, 7(8):432–437.
18. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN: Acquisition
of clostridium difficile by hospitalized patients: evidence for
colonized new admissions as a source of infection. JI n f e c tD i s1992,
166(3):561–567.
19. Starr JM, Campbell A, Renshaw E, Poxton IR, Gibson GJ: Spatio-temporal
stochastic modelling of clostridium difficile. J Hosp Infect 2009,
71(1):49–56.
20. Loo VG, Bourgault A-M, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B,
Beaudoin A, Frost EH, Gilca R, et al: Host and pathogen factors for
clostridium difficile infection and colonization. N Engl J Med 2011,
365(18):1693–1703.
21. Lanzas C, Dubberke ER, Lu Z, Reske KA, Grohn YT: Epidemiological model
for clostridium difficile transmission in healthcare settings. Infect Control
Hosp Epidemiol 2011, 32(6):553–561.
22. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper
EJ, Wilcox MH: The changing epidemiology of clostridium difficile
infections. Clin Microbiol Rev 2010, 23(3):529–549.
23. Kelly CP, LaMont JT: Clostridium difficile–more difficult than ever. N Engl J
Med 2008, 359(18):1932–1940.
24. Rupnik M, Wilcox MH, Gerding DN: Clostridium difficile infection: new
developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009,
7(7):526–536.
25. Best EL, Fawley WN, Parnell P, Wilcox MH: The potential for airborne
dispersal of clostridium difficile from symptomatic patients. Clin Infect Dis
2010, 50(11):1450–1457.
26. Roberts K, Smith CF, Snelling AM, Kerr KG, Banfield KR, Sleigh PA, Beggs CB:
Aerial dissemination of clostridium difficile spores. BMC Infect Dis 2008,
8:7–7.
27. Kyne L, Merry C, O’Connell B, Kelly A, Keane C, O’Neill D: Factors associated
with prolonged symptoms and severe disease due to clostridium
difficile. Age Ageing 1999, 28(2):107–113.
28. Bignardi GE: Risk factors for clostridium difficile infection. J Hosp Infect
1998, 40(1):1–15.
29. Johnson S: Recurrent clostridium difficile infection: a review of risk
factors, treatments, and outcomes. J Infect 2009, 58(6):403–410.
30. OECD: Health at a Glance 2011: OECD Indicators. OECD Publishing; 2011.
doi:10.1787/health_glance-2011-en.
31. MacDougall C, Polk R: Variability in rates of Use of antibacterials among
130 US hospitals and risk‐adjustment models for interhospital
comparison. Infect Control Hosp Epidemiol 2008, 29:203–211.
32. Polk R, Fox C, Mahoney A, Letcavage JCM: Measurement of adult
antibacterial drug Use in 130 US hospitals: comparison of defined daily
dose and days of therapy. Clin Infect Dis 2007, 44:664–670.
33. Rafii F, Sutherland J, Cerniglia C: Effects of treatment with antimicrobial
agents on the human colonic microflora. Ther Clin Risk Manag 2008,
4:1343–1358.
34. Keeling M, Rohani P: Modeling infectious diseases in humans and animals.
Princeton, NJ: Princeton University Press; 2007.
35. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN:
Nosocomial clostridium difficile colonisation and disease. Lancet 1990,
336(8707):97–9100.
36. McFarland LV: Update on the changing epidemiology of clostridium
difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2008, 5
(1):40–48.
37. Leffler DA, Lamont JT: Treatment of clostridium difficile-associated
disease. Gastroenterology 2009, 136(6):1899–1912.
38. Bartlett JG: Treatment of antibiotic-associated pseudomembranous
colitis. Rev Infect Dis 1984, 6(suppl 1):S235–S241.
39. McBryde ES, Pettitt AN, McElwain DLS: A stochastic mathematical model
of methicillin resistant staphylococcus aureus transmission in an
intensive care unit: predicting the impact of interventions. J Theor Biol
2007, 245(3):470–481.
40. Gillespie DT: Exact stochastic simulation of coupled chemical reactions.
J Phys Chem 1977, 81(25):2340–2361.
41. Muto CA, Blank MK, Marsh JW, Vergis EN, O’Leary MM, Shutt KA, Pasculle
AW, Pokrywka M, Garcia JG, Posey K, et al: Control of an outbreak of
infection with the hypervirulent clostridium difficile BI strain in a
Yakob et al. BMC Infectious Diseases 2013, 13:376 Page 7 of 8
http://www.biomedcentral.com/1471-2334/13/376university hospital using a comprehensive “bundle” approach. Clin Infect
Dis 2007, 45(10):1266–1273.
42. Walker AS, Eyre DW, Wyllie DH, Dingle KE, Harding RM, O’Connor L,
Griffiths D, Vaughan A, Finney J, Wilcox MH, et al: Characterisation of
clostridium difficile hospital ward-based transmission using extensive
epidemiological data and molecular typing. PLoS Med 2012,
9(2):e1001172.
43. Eastwood K, Else P, Charlett A, Wilcox M: Comparison of nine commercially
available clostridium difficile toxin detection assays, a real-time PCR
assay for C. Difficile tcdB, and a glutamate dehydrogenase detection
assay to cytotoxin testing and cytotoxigenic culture methods.
J Clin Microbiol 2009, 47(10):3211–3217.
44. Kyne L, Warny M, Qamar A, Kelly CP: Asymptomatic carriage of clostridium
difficile and serum levels of IgG antibody against toxin a. N Engl J Med
2000, 342(6):390–397.
45. Bauer MP, Kuijper EJ, van Dissel JT: European society of clinical
microbiology and infectious diseases (ESCMID): treatment guidance
document for clostridium difficile infection (CDI). Clin Microbiol Infect
2009, 15(12):1067–1079.
46. Khanna S, Pardi D, Aronson S, Kammer P, Orenstein R, St Sauver J, Harmsen
W, Zinsmeister A: The epidemiology of community-acquired clostridium
difficile infection: a population-based study. Am J Gastroenterol 2012,
107:89–95.
47. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D: Risk of clostridium
difficile diarrhea among hospital inpatients prescribed proton pump
inhibitors: cohort and case–control studies. Can Med Assoc J 2004,
171(1):33–38.
48. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault
A-M, Nguyen T, Frenette C, Kelly M, et al: A predominantly clonal multi-
institutional outbreak of clostridium difficile–associated diarrhea with
high morbidity and mortality. N Engl J Med 2005, 353(23):2442–2449.
49. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J: Clostridium
difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995,
16:459–477.
50. Mayfield JL, Leet T, Miller J, Mundy LM: Environmental control to reduce
transmission of clostridium difficile. Clin Infect Dis 2000, 31:995–1000.
51. Thomas C, Stevenson M, Williamson DJ, Riley TV: Clostridium difficile-
associated diarrhea: epidemiological data from western australia
associated with a modified antibiotic policy. Clin Infect Dis 2002,
35:1457–1462.
52. Aldeyab MA, Kearney MP, Scott MG, Aldiab MA, Alahmadi YM, Darwish
Elhajji FW, Magee FA, McElnay JC: An evaluation of the impact of
antibiotic stewardship on reducing the use of high-risk antibiotics and
its effect on the incidence of clostridium difficile infection in hospital
settings. J Antimicrob Chemother 2012, 67(12):2988–2996.
53. Jump RLPMDP, Olds DMRNP, Seifi NMS, Kypriotakis GMS, Jury LARNCNP,
Peron EPP, Hirsch AAP, Drawz PEMD, Watts BMD, Bonomo RAMD, et al:
Effective antimicrobial stewardship in a long-term care facility through
an infectious disease consultation service: keeping a LID on antibiotic
Use. Infect Control Hosp Epidemiol 2012, 33(12):1185–1192.
54. Nathwani D, Sneddon J, Malcolm W, Wiuff C, Patton A, Hurding S, Eastaway
A, Seaton RA, Watson E, Gillies E, et al: Scottish antimicrobial prescribing
group (SAPG): development and impact of the scottish national
antimicrobial stewardship programme. Int J Antimicrob Agents 2011,
38(1):16–26.
55. Valiquette L, Cossette B, Garant M-P, Diab H, Pépin J: Impact of a reduction
in the Use of high-risk antibiotics on the course of an epidemic of
clostridium difficile-associated disease caused by the hypervirulent
NAP1/027 strain. Clin Infect Dis 2007, 45(2):S112–S121.
56. Anderson RM, Garnett GP: Mathematical models of the transmission and
control of sexually transmitted diseases. Sex Transm Dis 2000, 27:636–643.
57. Nowak M, Anderson R, McLean A, Wolfs T, Goudsmit J, May R: Antigenic
diversity thresholds and the development of AIDS. Science 1991,
254:963–969.
58. Yakob L, Clements ACA: A mathematical model of chikungunya dynamics
and control: the major epidemic on réunion island. PLoS ONE 2013,
8(3):e57448.
59. Yakob L, Dunning R, Yan G: Indoor residual spray and insecticide-treated
bednets for malaria control: theoretical synergisms and antagonisms.
J R Soc Interface 2011, 8(59):799–806.
60. Yakob L, Yan G: Modeling the effects of integrating larval habitat source
reduction and insecticide treated nets for malaria control. PLoS ONE
2009, 4(9):e6921.
61. Ferguson N, Keeling MJ, Edmunds WJ, Gani R, Brenfell BT, Anderson RM,
Leach S: Planning for smallpox outbreaks. Nature 1991, 425:681–685.
62. Meyers LA: Contact network epidemiology: bond percolation applied to
infectious disease prediction and control. Bull Am Math Soc 2007,
44:63–86.
doi:10.1186/1471-2334-13-376
Cite this article as: Yakob et al.: Clostridium difficile exposure as an
insidious source of infection in healthcare settings: an epidemiological
model. BMC Infectious Diseases 2013 13:376.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Yakob et al. BMC Infectious Diseases 2013, 13:376 Page 8 of 8
http://www.biomedcentral.com/1471-2334/13/376